• EyePoint Reports Positive Results from GLP Toxicology Study of EYP-1901 americanpharmaceuticalreview
    December 24, 2020
    EyePoint Pharmaceuticals announced positive results from its good laboratory practice (GLP) preclinical toxicology study of EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment using its proprietary bioerodible Durasert® ...
PharmaSources Customer Service